Dr Alan M Jones Ph.D., BSc. (Hons), MRSC, FHEA

Dr Alan Jones

School of Pharmacy
Associate Professor in Medicinal Chemistry

Contact details

Institute of Clinical Sciences
University of Birmingham
B15 2TT

Alan is an Associate Professor in Medicinal and Pharmaceutical Chemistry, Drug Discovery Ambassador, Head of Year 2 of the MPharm programme, Chemistry for Pharmacists II module lead, the College of Medical and Dental Sciences (MDS) Chemical Safety Lead, and Institute of Clinical Sciences (ICS) Chemical Safety Advisor. He is the MDS lead for the University’s Health & Safety Advisory Group (UHSAG) and serves on the College Safety Executive Committee (CSEC) and the Deputy Chair of the Institute’s Health & Safety Committee.

His group’s research interest focusses on the application of synthetic and medicinal chemistry to solve challenges at the intersection of biology and drug discovery. This includes combining electrosynthesis with medicinal chemistry as an enabling technology in drug discovery and drug safety.

He has a wealth of experience of teaching and external examining at both undergraduate and postgraduate levels.


  • PG Cert 2016
  • FHEA 2016
  • Member of the Royal Society of Chemistry, 2009
  • Ph.D. University of St Andrews, 2009
  • BSc. Hons University of Aberdeen, 2005


Postgraduate supervision

Synthetic organic chemistry
Electrosynthetic Green Chemistry
Medicinal Chemistry and Chemical Biology

Other activities

Grant Reviewer

  • British Council Newton Fund, UK
  • Rosetrees Trust, UK
  • KidScan Cancer charity, UK
  • Parkinson’s UK
  • University of Sharjah, United Arab Emirates
  • Fondation pour la Recherche Médicale, France

Journal Peer Reviewer

ACS, RSC, Wiley, MDPI and Elsevier journal titles including:

  • Chemical Communications
  • Advanced Synthesis & Catalysis
  • ChemSusChem
  • Journal of Organic Chemistry
  • ACS Sustainable Chemistry & Engineering
  • Chemical Record
  • Chem. Eur. J.

Editorial roles

  • Molecules MDPI – Organic Chemistry section editor
  • Molecules MDPI – Guest Editor

External Examiner

  • University of Nottingham (UK) PhD
  • University of Cardiff (UK) PhD
  • University of Sunderland (UK) UG

Other collaborations


Recent publications


Asra, R & Jones, AM 2023, 'Green electrosynthesis of drug metabolites', Toxicology Research. https://doi.org/10.1093/toxres/tfad009

Povinelli, APR, Zazeri, G, Jones, AM & Cornélio, ML 2022, 'A computational–experimental investigation of the molecular mechanism of interleukin-6-piperine interaction', International Journal of Molecular Sciences, vol. 23, no. 14, 7994. https://doi.org/10.3390/ijms23147994

Salim, H & Jones, AM 2022, 'Angiotensin II receptor blockers (ARBs) and manufacturing contamination: a retrospective national register study into suspected associated adverse drug reactions', British Journal of Clinical Pharmacology, vol. 2022, no. 11, pp. 1-16. https://doi.org/10.1111/bcp.15411

O’Connor, S, Le Bihan, Y-V, Westwood, IM, Liu, M, Mak, OW, Zazeri, G, Povinelli, APR, Jones, AM, van Montfort, R, Reynisson, J & Collins, I 2022, 'Discovery and characterization of a cryptic secondary binding site in the molecular chaperone HSP70', Molecules, vol. 27, no. 3, 817. https://doi.org/10.3390/molecules27030817

Jones, L & Jones, AM 2022, 'Suspected adverse drug reactions of the type 2 antidiabetic drug class dipeptidyl-peptidase IV inhibitors (DPP4i): can polypharmacology help explain?', Pharmacology research & perspectives, vol. 10, no. 6, e01029. https://doi.org/10.1002/prp2.1029

Alshehri, J, Gill, D & Jones, AM 2021, 'A sulfuryl group transfer strategy to selectively prepare sulfated steroids and isotopically labelled derivatives', Frontiers in Molecular Bioscience, vol. 8, 776900. https://doi.org/10.3389/fmolb.2021.776900, https://doi.org/10.3389/fmolb.2021.776900

Jones, AM 2021, 'Dialling-in new reactivity into the Shono-type anodic oxidation reaction', The Chemical Record, vol. 21, no. 9, pp. 2120-2129. https://doi.org/10.1002/tcr.202000116

Sandhu, D, Antolin, A, Cox, A & Jones, AM 2021, 'Identification of different side effects between PARP inhibitors and their polypharmacological multi-target rationale', British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15015

Kladnik, J, Coverdale, JPC, Kljun, J, Burmeister, H, Lippman, P, Ellis, FG, Jones, AM, Ott, I, Romero-Canelón, I & Turel, I 2021, 'Organoruthenium complexes with benzo-fused pyrithiones overcome platinum resistance in ovarian cancer cells', Cancers, vol. 13, no. 10, 2493. https://doi.org/10.3390/cancers13102493

Matharu, K, Chana, K, Ferro, C & Jones, AM 2021, 'Polypharmacology of clinical sodium glucose co-transport protein 2 inhibitors and relationship to suspected adverse drug reactions', Pharmacology Research and Perspectives, vol. 9, no. 5, e00867. https://doi.org/10.1002/prp2.867

Gill, D, Ribeiro Povinelli, A, Zazeri, G, Shamir, SA, Mahmoud, AM, Wilkinson, FL, Alexander, MY, Cornelio, ML & Jones, AM 2021, 'The modulatory role of sulfated and non-sulfated small molecule heparan sulfate-glycomimetics in endothelial dysfunction: Absolute structural clarification, molecular docking and simulated dynamics, SAR analyses and ADMET studies', RSC Medicinal Chemistry, vol. 12, no. 5, pp. 779-790. https://doi.org/10.1039/D0MD00366B

Ribeiro Povinelli, A, Zazeri, G, Jones, AM & Cornelio, ML 2021, 'Unravelling the interaction of piperlongumine with the nucleotide-binding domain of HSP70: a spectroscopic and in silico study', Pharmaceuticals (Basel, Switzerland), vol. 14, no. 12, 1298. https://doi.org/10.3390/ph14121298

Entry for encyclopedia/dictionary

Jones, AM 2021, Tributylsulfoammonium betaine. in A Charette, J Bode, T Rovis & R Shenvi (eds), e-EROS: Encyclopedia of Reagents for Organic Synthesis. Electronic Encyclopedia of Reagents for Organic Synthesis, Wiley. https://doi.org/https://onlinelibrary.wiley.com/doi/full/10.1002/047084289X.RN02393, https://doi.org/10.1002/047084289X.rn02393


Zhou, Y & Jones, AM 2022 'A Sulfonative rearrangement of N-aryl sulfamates to para-sulfonyl anilines' ChemRxiv. https://doi.org/10.26434/chemrxiv-2022-jc55l

Jones, L & Jones, AM 2022 'Suspected adverse drug reactions of the type 2 antidiabetic drug class dipeptidyl-peptidase IV inhibitors (DPP4i): can polypharmacology help explain?' medRxiv. https://doi.org/10.1101/2022.06.30.22277085

View all publications in research portal